Home Cart Sign in  
Chemical Structure| 10102-94-0 Chemical Structure| 10102-94-0

Structure of 10102-94-0

Chemical Structure| 10102-94-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 10102-94-0 ]

CAS No. :10102-94-0
Formula : C10H8BrNO
M.W : 238.08
SMILES Code : O=CC1=CN(C)C2=C1C=C(Br)C=C2
MDL No. :MFCD03906373
InChI Key :NZJJLQUTQOICBN-UHFFFAOYSA-N
Pubchem ID :778451

Safety of [ 10102-94-0 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 10102-94-0 ] Show Less

Physicochemical Properties

Num. heavy atoms 13
Num. arom. heavy atoms 9
Fraction Csp3 0.1
Num. rotatable bonds 1
Num. H-bond acceptors 1.0
Num. H-bond donors 0.0
Molar Refractivity 56.29
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

22.0 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.12
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

2.15
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.75
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.88
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.74
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

2.33

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.12
Solubility 0.182 mg/ml ; 0.000764 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.24
Solubility 1.36 mg/ml ; 0.0057 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.65
Solubility 0.0529 mg/ml ; 0.000222 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

Yes
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.23 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.34

Application In Synthesis of [ 10102-94-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 10102-94-0 ]

[ 10102-94-0 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 10102-94-0 ]
  • [ 41003-94-5 ]
  • [ 90289-62-6 ]
  • [ 90289-63-7 ]
YieldReaction ConditionsOperation in experiment
90.1% General procedure: 5-Fluoroindole-3-carbaldehyde (0.5 g, 3.07 mmol) and tetrahydrofuran (10 mL) were sequentially added to a 100 mL one-neck round bottom flask, cooled to 0 C, and slowly added NaH (60%, 196 mg, 4.91 mmol) After reacting for 10 minutes,Transfer to room temperature for 1 h, add MeI (0.38 mL, 6.14 mmol),The reaction was carried out at room temperature for 15.5 h, quenched with water (5 mL), and then evaporated to ethyl ether (ethyl acetate) (ethyl acetate (40mL×1)), washed with water (20mL×3), and then ethyl acetate was collected and then purified by column chromatography ( petroleum ether) /ethyl acetate (v/v) = 5/1) to give the title compound as a white solid(0.50 g, 92%).
  • 4
  • [ 19012-03-4 ]
  • [ 10102-94-0 ]
  • [ 25055-65-6 ]
  • [ 25055-66-7 ]
  • N-methyl-2,6-dibromoindole-3-carbaldehyde [ No CAS ]
  • 5
  • [ 877-03-2 ]
  • [ 74-88-4 ]
  • [ 10102-94-0 ]
YieldReaction ConditionsOperation in experiment
96% 5-bromoindole-3-carbaldehyde 2 (10 mmol) was dissolved in acetonitrile and to this powdered NaOH (5 mmol) was added and stirred for 10 min. Methyl iodide (10 mmol) was added dropwise to the reaction mixture. After 3h of stirring at room temperature, the solvent was completely evaporated. It was extracted with ethyl acetate (3x20 ml) and dried over Na2SO4. The combined organic layer was concentrated in vacuo to give a light yellow color solid purified by recrystallization with diethyl ether. Pale yellow solid; Yield: 96%; mp 122-124 C; IR (KBr) numax 3103, 2923, 2813, 1700, 1654. 1533, 1467, 1369, 1083, 799, 726; 1H NMR (DMSO-d6, 300 MHz) delta 9.88 (s, 1H), 8.33 (s, 1H), 8.23 (d, J = 1.70 Hz, 1H), 7.60 (d, J = 8.68 Hz, 1H), 7.48 (dd, J = 2.08, 8.87 Hz, 1H), 3.89 (s, 3H); TOF-HRMS (m/z) for C10H8BrNO, calculated 237.9862, observed 237.9855 [M+1] +
91% With sodium hydride; In tetrahydrofuran; at 0℃; for 1.83333h; 5-Bromo-1-methyl-lH-indole-3-carbaldehyde; 5-Bromo-1H-indole-3-carbaldehyde (4.8 mmol, 1076 mg) was dissolved in 15 mL of THF and the solution was cooled to 0 C under N2-athmosphere. Sodium hydride (11.7 mmol, 280 mg) was added carefully in portions and iodomethane (8.1 mmol, 1150 mg) was added. The mixture was stirred at 0 C for 1 h. More iodomethane (8.1 mmol, 1150 mg) was added and the stirring continued for 50 min. The mixture was poured over ice and the resulting slurry was extracted with EtOAc. The organic layer was dried over Na2SO4, filtered and evaporated. This gave 1037 mg (91 %) of the title product. 'H NMR (400 MHz, MeOH-d4) 8 9.82 (s, 1H), 8,29 (m, 1H), 8.06 (s, 1H), 7.43 (m, 2H), 3.89 (s, 3H)
81% General procedure: To a suspension of NaH 60% in oil (2.25 equiv.) in dry DMF(0.8 mL/mmol) was added, at 0 C and under nitrogen atmosphere, a solution of indolecarboxaldehyde (1 equiv.) in dry DMF (2.5 mL/mmol). After stirring for 30 min at rt, alkyl halide (1.0e3.0 equiv.)was slowly added. After stirring overnight, the reaction wasquenched by addition of water and the product was extracted withdiethyl ether. The organic layer was dried over MgSO4, filtered offand concentrated under vacuum. The crude product was purifiedby column chromatography on silica gel.
General procedure: Compounds 7-9 were synthesized from the corresponding compounds 4-6. A solution of compounds 4-6 (60 mmol) in THF (30 mL) were added dropwise to a suspension of NaH (3.60 g, 60% dispersion in mineral oil, 150 mmol) in THF (30 mL) at 0 C. After stirring for 15 min, the heterogeneous mixture was treated with iodomethane (5.04 mL, 79.2 mmol) at room temperature for 1 h. Then the reaction mixture was cooled to 0 C, quenched with saturated NH4Cl (60 mL), and extracted with ether (3 * 50 mL). The organic layers were combined, washed with brine, dried over anhydrous Na2SO4 and concentrated in vacuo to give 1-Methyl-1H-indole-3-carboxaldehyde (7-9), a light brown solid. The crude 7-9 were used in the next step without any further purification.
With sodium hydride; In tetrahydrofuran; at 0 - 20℃; for 24h; General procedure: The relevant indole-3-carboxaldehyde (2a-c, 10 mmol) in THF(25 mL) was added dropwise to a stirred solution of NaH (25 mmol)in THF (25 mL) at 0 C and CH3I (13.2 mmol) was added after 15 minstirring. The reaction mixturewas moved to room temperature andstirred for further 24 h. Then the solvent was removed in vacuumand the residue was extracted by ethyl acetate. The organic layerwas washed with brine, dried over anhydrous sodium sulfate,filtered and concentrated in vacuum. Recrystallization affordedcompound 3a-c with yields of 93.4-97.5%.

  • 7
  • [ 10102-94-0 ]
  • [ 38622-91-2 ]
  • 5-(5'-bromo-1'-methyl-3'-indolyl)oxazole [ No CAS ]
  • 8
  • [ 10102-94-0 ]
  • [ 31499-72-6 ]
  • 1-(5-bromo-1-methyl-1H-indol-3-yl)-5-(2,6,6-trimethylcyclohex-2-enyl)-pent-1-en-3-one [ No CAS ]
  • 9
  • [ 10102-94-0 ]
  • [ 7333-52-0 ]
  • 5-bromo-3-cyclopentylidenemethyl-1-methyl-1<i>H</i>-indole [ No CAS ]
  • 10
  • [ 931127-52-5 ]
  • [ 10102-94-0 ]
  • 4-(5-bromo-1-methyl-1<i>H</i>-indol-3-ylmethylene)-5-[1,2,3]thiadiazol-5-yl-2,4-dihydro-pyrazol-3-one [ No CAS ]
  • 12
  • [ 10102-94-0 ]
  • C30H32Br2N2 [ No CAS ]
  • 13
  • [ 10102-94-0 ]
  • 5-bromo-1-methyl-1<i>H</i>-indole-3-carboxylic acid pyridin-4-ylamide [ No CAS ]
  • 14
  • [ 10102-94-0 ]
  • 5-bromo-1-methyl-1<i>H</i>-indole-3-carboxylic acid (4,6-dimethyl-pyridin-2-yl)-amide [ No CAS ]
  • 15
  • [ 860297-17-2 ]
  • [ 10102-94-0 ]
  • C27H31BrN4O [ No CAS ]
  • 17
  • [ 10102-94-0 ]
  • [ 3481-02-5 ]
  • C20H18BrNO2 [ No CAS ]
  • 19
  • [ 10102-94-0 ]
  • [ 1338059-25-8 ]
  • 20
  • [ 10102-94-0 ]
  • [ 1338059-33-8 ]
  • 21
  • [ 877-03-2 ]
  • [ 105-58-8 ]
  • [ 10102-94-0 ]
  • 22
  • [ 10102-94-0 ]
  • [ 1284312-44-2 ]
  • 24
  • [ 10102-94-0 ]
  • [ 1021450-38-3 ]
  • 25
  • [ 10102-94-0 ]
  • [ 105-56-6 ]
  • [ 1363417-35-9 ]
  • 27
  • [ 10102-94-0 ]
  • [ 1391815-97-6 ]
  • 28
  • [ 10102-94-0 ]
  • [ 20356-45-0 ]
  • [ 1391815-92-1 ]
  • 29
  • [ 10075-52-2 ]
  • [ 110-18-9 ]
  • [ 10102-94-0 ]
YieldReaction ConditionsOperation in experiment
70% With water; iodine; oxygen; sodium carbonate; In 1,4-dioxane; at 100℃; under 760.051 Torr; for 60h;Schlenk technique; Sealed tube; General procedure: Under air, a 20 mL of Schlenk tube equipped with a stir bar was charged with indole 1 (0.2 mmol, 1 equiv),TMEDA (75 muL, 0.5 mmol, 2.5 equiv), Na2CO3 (42.4 mg, 0.4mmol, 2.0 equiv), 1,4-dioxane (0.5 mL) and H2O (100 muL). Then I2 (101.5 mg, 0.4 mmol, 2.0 equiv) was added and the tube was sealed with a rubber plug and charged with O2. The reaction mixture was stirred at 100 C for 36 h in oil bath. After cooling to room temperature, the resultant mixture was evaporated with EtOAc (20 mL) under reduced pressure and the residue was purified by flash column chromatography on a silica gel to give the products.
  • 30
  • [ 10102-94-0 ]
  • [ 622-79-7 ]
  • [ 1421616-86-5 ]
  • 31
  • [ 10075-52-2 ]
  • [ 68-12-2 ]
  • [ 10102-94-0 ]
  • 33
  • [ 10102-94-0 ]
  • [ 1421592-41-7 ]
  • 35
  • [ 2295-31-0 ]
  • [ 10102-94-0 ]
  • [ 1421592-33-7 ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 10102-94-0 ]

Bromides

Chemical Structure| 17826-04-9

A133135 [17826-04-9]

6-Bromo-1H-indole-3-carbaldehyde

Similarity: 0.93

Chemical Structure| 400071-95-6

A700371 [400071-95-6]

5-Bromo-1-methyl-1H-indole-3-carboxylic acid

Similarity: 0.86

Chemical Structure| 10075-49-7

A167400 [10075-49-7]

5-Bromo-1,3-dimethyl-1H-indole

Similarity: 0.85

Chemical Structure| 332366-57-1

A223428 [332366-57-1]

6-Bromoquinolin-4(1H)-one

Similarity: 0.84

Chemical Structure| 944086-09-3

A194877 [944086-09-3]

1-(7-Bromo-1H-indol-3-yl)ethanone

Similarity: 0.83

Aldehydes

Chemical Structure| 17826-04-9

A133135 [17826-04-9]

6-Bromo-1H-indole-3-carbaldehyde

Similarity: 0.93

Chemical Structure| 98600-34-1

A196612 [98600-34-1]

4-Bromoindole-3-carboxyaldehyde

Similarity: 0.82

Chemical Structure| 877-03-2

A326792 [877-03-2]

5-Bromo-1H-indole-3-carbaldehyde

Similarity: 0.82

Chemical Structure| 19012-03-4

A117213 [19012-03-4]

1-Methyl-1H-indole-3-carbaldehyde

Similarity: 0.80

Chemical Structure| 133994-99-7

A214069 [133994-99-7]

1-Methyl-1H-indole-4-carbaldehyde

Similarity: 0.77

Related Parent Nucleus of
[ 10102-94-0 ]

Indoles

Chemical Structure| 17826-04-9

A133135 [17826-04-9]

6-Bromo-1H-indole-3-carbaldehyde

Similarity: 0.93

Chemical Structure| 400071-95-6

A700371 [400071-95-6]

5-Bromo-1-methyl-1H-indole-3-carboxylic acid

Similarity: 0.86

Chemical Structure| 10075-49-7

A167400 [10075-49-7]

5-Bromo-1,3-dimethyl-1H-indole

Similarity: 0.85

Chemical Structure| 944086-09-3

A194877 [944086-09-3]

1-(7-Bromo-1H-indol-3-yl)ethanone

Similarity: 0.83

Chemical Structure| 98600-34-1

A196612 [98600-34-1]

4-Bromoindole-3-carboxyaldehyde

Similarity: 0.82